Truist initiated coverage of BeOne Medicines (ONC) with a Buy rating and $400 price target The firm expect Brukinsa’s revenue stream to sustainably support the company’s operations and drive BeOne Medicines toward the guided positive free cash flow by 2025, the analyst tells investors in a research note. The company’s leadership position in CLL – chronic lymphocytic leukemia – is well-solidified by Brukinsa’s differentiation and the franchise’s comprehensive growth strategy, including proprietary next-wave assets such as sonrotoclax and BTK CDAC, Truist added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines Secures $1 Billion Financing Agreement
- BeOne Medicines price target raised to $408 from $395 at RBC Capital
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- BeOne Medicines: Buy Rating Driven by Robust Global Vision and Strong Financial Performance
- BeOne Medicines price target raised to $420 from $398 at Jefferies